Researchers found that a new cell therapy called Sasineprocel may help people with Parkinson’s disease experience significant improvements in their daily lives. In a small clinical trial, patients reported gaining about two extra hours of “good” time each day, meaning they felt better and more functional. Additionally, their scores on a common Parkinson’s disease assessment improved by an average of 15 points, indicating less severe symptoms. Quality of life also saw a boost, with participants in the lower-dose group reporting a 51.6% improvement.

This therapy uses a patient’s own cells, which reduces the risk of immune rejection and eliminates the need for ongoing immunosuppression. For those living with Parkinson’s, this could mean a more manageable condition with fewer side effects from traditional medications. The trial involved eight patients and showed promising results, suggesting that Sasineprocel could offer a new avenue for treatment, particularly for those struggling with the debilitating effects of the disease.

The research is still in its early stages, having just completed a Phase 1/2a trial. While the findings are encouraging, they are based on a small group of participants, so further studies are needed to confirm the effectiveness and safety of this therapy in larger populations. Aspen, the company behind Sasineprocel, plans to initiate a Phase 3 trial in 2026 after discussing the next steps with the FDA. For now, those interested in Parkinson’s treatments should stay informed about ongoing research and consider discussing new options with their healthcare providers.

Source: longevity.technology